Level	Gene	Alterations	Cancer Types	Drugs (for therapeutic implications only)
1	BRAF	V600E	All Solid Tumors (excluding Colorectal Cancer)	Dabrafenib + Trametinib
1	ERBB2	Amplification	Breast Cancer	Ado-Trastuzumab Emtansine
1	ERBB2	Amplification	Breast Cancer	Lapatinib + Capecitabine, Lapatinib + Letrozole
1	ERBB2	Amplification	Breast Cancer	Margetuximab + Chemotherapy
1	ERBB2	Amplification	Breast Cancer	Neratinib, Neratinib + Capecitabine
1	ERBB2	Amplification	Breast Cancer	Trastuzumab + Pertuzumab + Chemotherapy
1	ERBB2	Amplification	Breast Cancer	Trastuzumab + Tucatinib + Capecitabine
1	ERBB2	Amplification	Breast Cancer	Trastuzumab Deruxtecan
1	ERBB2	Amplification	Breast Cancer	Trastuzumab, Trastuzumab + Chemotherapy
1	ESR1	D538, E380, L469V, L536, S463P, Y537	Breast Cancer	Elacestrant
1	NTRK1	Fusions	All Solid Tumors	Entrectinib
1	NTRK1	Fusions	All Solid Tumors	Larotrectinib
1	NTRK2	Fusions	All Solid Tumors	Entrectinib
1	NTRK2	Fusions	All Solid Tumors	Larotrectinib
1	NTRK3	Fusions	All Solid Tumors	Entrectinib
1	NTRK3	Fusions	All Solid Tumors	Larotrectinib
1	Other Biomarkers	Microsatellite Instability-High	All Solid Tumors	Pembrolizumab
1	Other Biomarkers	Tumor Mutational Burden-High	All Solid Tumors	Pembrolizumab
1	PIK3CA	C420R, E542K, E545A, E545D, E545G, E545K, H1047L, H1047R, H1047Y, Q546E, Q546R	Breast Cancer	Alpelisib + Fulvestrant
1	RET	Fusions	All Solid Tumors (excluding Thyroid Cancer, Non-Small Cell Lung Cancer)	Selpercatinib
R1	NTRK1	G595R	All Solid Tumors	Larotrectinib
R1	NTRK3	F617L	All Solid Tumors	Larotrectinib
R1	NTRK3	G623R	All Solid Tumors	Larotrectinib
R1	NTRK3	G696A	All Solid Tumors	Larotrectinib
2	PIK3CA	Oncogenic Mutations (excluding C420R, E542K, E545A, E545D, E545G, E545K, Q546E, Q546R, H1047L, H1047R and H1047Y)	Breast Cancer	Alpelisib + Fulvestrant
3	AKT1	E17K	Breast Cancer	AZD5363
3	BRCA1	Oncogenic Mutations	Breast Cancer	Olaparib
3	BRCA1	Oncogenic Mutations	Breast Cancer	Talazoparib
3	BRCA2	Oncogenic Mutations	Breast Cancer	Olaparib
3	BRCA2	Oncogenic Mutations	Breast Cancer	Talazoparib
3	ERBB2	Oncogenic Mutations	Breast Cancer	Neratinib
3	ESR1	Oncogenic Mutations (excluding Fusions)	Breast Cancer	Fulvestrant
3	ESR1	V422del	Breast Cancer	Elacestrant
3	NRG1	Fusions	All Solid Tumors	Zenocutuzumab
3	NTRK1	Fusions	All Solid Tumors	Repotrectinib
3	NTRK2	Fusions	All Solid Tumors	Repotrectinib
3	NTRK3	Fusions	All Solid Tumors	Repotrectinib
3	TP53	Y220C	All Solid Tumors	PC14586
4	ARID1A	Truncating Mutations	All Solid Tumors	PLX2853
4	ARID1A	Truncating Mutations	All Solid Tumors	Tazemetostat
4	BRAF	G464, G469A, G469R, G469V	All Solid Tumors	PLX8394
4	BRAF	K601	All Solid Tumors	PLX8394
4	BRAF	L597	All Solid Tumors	PLX8394
4	CCNE1	Amplification	All Solid Tumors	RP-6306, BLU-222
4	CDK12	Truncating Mutations	All Solid Tumors	Pembrolizumab, Nivolumab, Cemiplimab
4	CDKN2A	Oncogenic Mutations	All Solid Tumors	Palbociclib, Ribociclib, Abemaciclib
4	FGFR1	Oncogenic Mutations	All Solid Tumors	Debio1347, Infigratinib, Erdafitinib, AZD4547
4	FGFR2	Oncogenic Mutations	All Solid Tumors	Debio1347, Infigratinib, Erdafitinib, AZD4547
4	FGFR3	Oncogenic Mutations	All Solid Tumors	Debio1347, Infigratinib, Erdafitinib, AZD4547
4	KRAS	G12D	All Solid Tumors	RMC-6236
4	KRAS	Oncogenic Mutations	All Solid Tumors	Trametinib, Cobimetinib, Binimetinib
4	MET	Fusions	All Solid Tumors	Crizotinib
4	MTOR	Oncogenic Mutations	All Solid Tumors	Everolimus, Temsirolimus
4	NF1	Oncogenic Mutations	All Solid Tumors	Trametinib, Cobimetinib
4	PIK3CA	H1047R	All Solid Tumors (excluding Colorectal Cancer)	LOXO-783
4	PIK3CA	H1047R	Breast Cancer	LOXO-783 + Fulvestrant, LOXO-783 + Fulvestrant + Abemaciclib, LOXO-783 + LY3484356, LOXO-783 + LY3484356 + Abemaciclib, LOXO-783 + Aromatase Inhibition Therapy + Abemaciclib, LOXO-783 + Paclitaxel
4	PIK3CA	Oncogenic Mutations	All Solid Tumors	RLY-2608
4	PIK3CA	Oncogenic Mutations	Breast Cancer	RLY-2608 + Fulvestrant
4	PTEN	Oncogenic Mutations	All Solid Tumors	GSK2636771, AZD8186
R2	NTRK1	G595R	All Solid Tumors	Entrectinib